501-3292
Production Way, Burnaby, B.C., V5A 4R4
Phone:
(604) 551-7831 Fax:
604-676-2767
info@cannabixtechnologies.com
cannabixtechnologies.com
Cannabix
Technologies
Expands
Marijuana Breathalyzer Portfolio with
Licensing of UBC Technology for
Workplace and Parental Use
Cannabix
and UBC are working together to develop marijuana breathalyzer
technology for a range of markets
Vancouver, British
Columbia -- September
23, 2019
--
InvestorsHub NewsWire -- Cannabix
Technologies Inc.
(CSE: BLO) (OTC PINK: BLOZF) (the "Company or Cannabix")
developer
of the Cannabix
Marijuana
Breathalyzer is pleased to report that the
Company
has
entered into an exclusive license agreement with the University of
British Columbia ("UBC")
to use and commercialize certain technology for the detection of
volatile organic compounds for testing (to be used for
marijuana
breathalyzer purposes)
owned
by UBC
developed
by Dr. Mina Hoofar
and her
team of
researchers at the UBC Okanagan
School of Engineering. The
patent
pending UBC technology known
as a "THC Breath
Analyzer" ("THCBA")
incorporates highly
sensitive microfluidic sensors that can be manufactured at
relatively low cost. This
exclusive
technology license will allow for
Cannabix
to offer
a complementary
low-cost
portable
breathalyzer device that would be ideally suited for
workplace, parental and
personal
use testing. Cannabix's
advanced
"FAIMS"
(field
asymmetric waveform ion mobility spectrometry) based
marijuana
breathalyzer system
will
be primarily
focussed
on
roadside
testing with law
enforcement and toxicology lab
confirmation. UBC is
developing
the
THCBA
on an
accelerated pace and Cannabix
anticipates that a
breathalyzer device is expected to
be available for
expanded
testing this
fall/winter.
Significant
development work has been accomplished on
the
THCBA
by UBC
and images
of
the
of the
THCBA portable
device (under
development) can be viewed at
cannabixtechnologies.com (and are included in
this press release).
The
Company believes that the professional needs of
law enforcement users (use at police stations and
court
acceptance) will likely differ
from the needs of employers, and civilian users of such devices.
Specificity of use, pricing,
ruggedization, disposables and calibration
requirements will all be factors in delivering multiple
breathalyzer products
that meet the needs of specific
customers. The
THCBA
technology will offer
a relatively low-cost
alternative to the
professional grade selectivity and sensitivity offered by
the Cannabix
FAIMS
marijuana breathalyzer. Cannabix's
FAIMS
device allows
for mass
spectrometry (MS) laboratory confirmation with its unique ability
to couple directly to MS. With both
devices being developed by Cannabix,
the Company aims to significantly expand its potential base of
customers for its products and services.
Rav
Mlait,
CEO of Cannabix
stated,
"We are extremely excited about this
opportunity to add
this
complementary
technology license
to our
product portfolio. The joint
UBC-Cannabix
collaboration on this
low-cost marijuana breath testing technology will facilitate our
strategy to better segment market opportunities with multiple
devices. The marijuana
breathalyzer technology universe is in its early stages, and it
is strategically
important for Cannabix
to
commercialize
technologies
that
can bolster its ability
to offer a range of products to meet the needs of different
customer segments. We believe that
diversifying our technology holdings will be important as
regulators worldwide begin to understand the different types of
cannabis breathalyzer/detection technologies that are emerging. We
want to be well prepared to meet evolving evidentiary regulatory
standards for drug
breath
testing technologies."
Dr.
Mina Hoofar
stated,
"It is always exciting
to see our research, that originates on the Okanagan campus of UBC,
extend to the next stage of development.
We are
thrilled that through this collaboration,
devices will soon enter the market for self-monitoring and
usage as a
marijuana
breathalyzer.
This collaboration
will
bring our findings to market providing users with affordable,
portable, fast and accurate devices.
Collaborating
with Cannabix
means
that we can leverage their expertise in marketing and
implementation, bringing the THC Breath Analyzer one step closer to
entering the market.
We look
forward to future collaborations with Cannabix
as we
continue to strive for innovation in the fields of micro-fluidics
and bio-marker analysis."
The
Company also reports
granting
2 million incentive stock options exercisable at $0.80 cents per
share for five years to officers and
directors
and two years for consultants.
About
Cannabix
Technologies
Inc.
Cannabix
Technologies Inc. is
a leader in marijuana breathalyzer development for law enforcement
and the workplace. Cannabix
has
established breath testing technologies in the pursuit of
bringing portable
tools to
market to enhance detection of marijuana impaired driving offences
on roads at a time when marijuana is becoming legal in many
jurisdictions globally.
Cannabix
is
working to develop drug-testing devices that will detect THC- the
psychoactive component of marijuana that causes intoxication- using
breath samples. In particular, Cannabix
is
focused on developing breath testing devices for detection of
recent use of THC, in contrast to urine testing for THC metabolite
that requires an invasive collection and reflects
usage,
days or
even weeks earlier. The
devices will also be useful for other practical applications such
as testing employees in the workplace where impairment
by THC
can be hazardous and for personal use
testing.
We seek
Safe Harbor.
On
behalf of the Board of Directors
"Rav
Mlait"
CEO
Cannabix
Technologies
Inc.
For
further information, contact the Company at
info@cannabixtechnologies.com
The
CSE has not reviewed and does not accept responsibility for the
adequacy or accuracy of this release.
Cautionary Statement
Regarding Forward-Looking Statements
This
press release contains forward-looking information that involves
various risks and uncertainties regarding future events. Such
forward-looking information can include without limitation
statements based on current expectations involving a number of
risks and uncertainties and are not guarantees of future
performance of the Company, such as final development of a
commercial or prototype product(s), successful trial or pilot of
company technologies, no assurance that commercial sales of any
kind actually materialize; no assurance the Company will have
sufficient funds to complete product development. There are
numerous risks and uncertainties that could cause actual results
and the Company's plans and objectives to differ materially from
those expressed in the forward-looking information, including:
(i) adverse market
conditions; (ii) risks regarding protection of proprietary
technology; (iii) the ability of the Company to complete
financings; (iv) the ability of the Company to develop and market
its future product; and (v) risks regarding government regulation,
managing and maintaining growth, the effect of adverse publicity,
litigation, competition and other factors which may be identified
from time to time in the Company's public announcements and
filings. There is no assurance that the marijuana breathalyzer
business will provide any benefit to the Company, and no assurance
that any proposed new products will be built or proceed. There is
no assurance that existing "patent pending" technologies licensed
by the Company will receive patent status by regulatory
authorities. The Company is not currently selling commercial
breathalyzers. Actual results and future events could differ
materially from those anticipated in such information. These and
all subsequent written and oral forward-looking information are
based on estimates and opinions of management on the dates they are
made and are expressly qualified in their entirety by this notice.
Except as required by law, the Company does not intend to update
these forward-looking statements.